Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck

Flavio Kruter, Mario Eisenberger, Victoria Sinibaldi, Christine Engstrom, Maria Jacobs, Jeffrey Abrams, Chandra Belani, William Gray, Steven Krasnow

Research output: Contribution to journalArticle

Abstract

Fifteen patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck received a 5 day continuous I.V. infusion of 6-thioguanine repeated every five weeks. Dose limiting toxicity was primarily hematological with grade III/IV leucopenia and thrombocytopenia seen in seven patients. Nausea and vomiting was moderate and well controlled with antiemetics. No complete or partial responses were observed, with a median time to progression of 58 days and a median survival of 227 + days for the entire group. Based on these results we do not recommend I.V. 6-thioguanine for the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)89-91
Number of pages3
JournalInvestigational New Drugs
Volume10
Issue number2
DOIs
StatePublished - Jun 1 1992
Externally publishedYes

    Fingerprint

Keywords

  • I.V. 6-thioguanine for recurrent/metastatic head and neck cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this